Medicure (TSX-V:MPH) today announced that pitavastatin magnesium (ZYPITAMAG^TM) tablets are now available in retail pharmacies throughout the United States. ZYPITAMAG^TM, a statin (HMG-CoA reductase inhibitor) medication approved by the U.S. Food and Drug Administration in July 2017, is available in strengths of 1 mg, 2 mg and 4 mg. ZYPITAMAG^TM is indicated for the treatment of patients with primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet, to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B (Apo B), triglycerides, and to increase high-density lipoprotein cholesterol. (Refer to the annexure appended below for the complete indication statement and important safety information.)

“Medicure is pleased to partner with Cadila Healthcare Ltd., India (Zydus group) and add ZYPITAMAG^TM to its cardiovascular commercial operation. This partnership offers a cost effective pitavastatin alternative and fits with Medicure’s mission of being a significant, value based, cardiovascular pharmaceutical company focused on the U.S. market,” commented Medicure’s President and CEO, Dr. Albert D. Friesen.

As previously announced Medicure entered into an agreement with Zydus to commercialize ZYPITAMAG^TM for a term of seven years, with extensions to the term available. ZYPITAMAG^TM was developed by Zydus via a 505(b)(2) New Drug Application procedure. Medicure is a U.S. pharmaceutical company and has a proven track-record of successful commercialization of products in the therapeutic segments of cardiovascular and metabolic diseases. As a part of this agreement, Zydus will hold the NDA and Medicure will be responsible for the sales and marketing of ZYPITAMAG^TM.

About Medicure

Medicure is a pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. cardiovascular market. The primary focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG^TM (pitavastatin magnesium) in the United States, where they are sold through the Company’s U.S. subsidiary, Medicure Pharma, Inc. For more information on Medicure please visit www.medicure.com.

About Zydus Cadila

Cadila Healthcare Ltd., India is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.  The group employs over 21000 people worldwide and is dedicated to creating healthier communities globally.  Zydus aspires to be a research-based pharmaceutical company by 2020.